Cargando…
Metformin prevents nephrolithiasis formation by inhibiting the expression of OPN and MCP-1 in vitro and in vivo
Treatment targeting osteopontin (OPN) and monocyte chemoattractant protein 1 (MCP-1) has been recognized as a novel approach in renal crystal formation. The present study was designed to investigate the suppressive effects of metformin on nephrolithiasis formation and its potential mechanism. The cy...
Autores principales: | Yang, Xiong, Yang, Tong, Li, Jie, Yang, Rui, Qi, Shiyong, Zhao, Yang, Li, Liang, Li, Jingjin, Zhang, Xuening, Yang, Kuo, Xu, Yong, Liu, Chunyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414169/ https://www.ncbi.nlm.nih.gov/pubmed/30720053 http://dx.doi.org/10.3892/ijmm.2019.4084 |
Ejemplares similares
-
Metformin Prevents Renal Stone Formation through an Antioxidant Mechanism In Vitro and In Vivo
por: Yang, Xiong, et al.
Publicado: (2016) -
Association between OPN genetic variations and nephrolithiasis risk
por: Xiao, Xu, et al.
Publicado: (2016) -
AB261. Metformin prevents renal stone formation through an antioxidant mechanism in vitro and in vivo
por: Yang, Xiong, et al.
Publicado: (2016) -
Biological and Clinicopathological Characteristics of OPN in Cervical Cancers
por: Qin, Shuhang, et al.
Publicado: (2022) -
Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells In Vitro and In Vivo
por: Tang, Jian-Cai, et al.
Publicado: (2017)